Neurocrine Expects INGREZZA Revenue Growth in 2027 on Volume Gains

Neurocrine Biosciences expects INGREZZA revenue to rise again in 2027 as double-digit volume growth more than offsets anticipated mid- to high-single-digit net pricing pressure, Chief Financial Officer Matthew Abernethy said Monday, Nov. 2. “Looking ahead to 2027, we expect continued double-digit INGREZZA volume growth to more than offset anticipated mid- to high single-digit net pricing headwinds, supporting another year of revenue growth,” Abernethy said on the company’s earnings call. Neurocrine has not set a numerical 2027 sales target.

Source: TokenPost